Unusual lipid structures selectively reduce the toxicity of amphotericin B. - Wikidata - wikimedia - TriplyDB

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

http://www.wikidata.org/entity/Q33641360

about

Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone).Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.Lipid-based amphotericin B for the treatment of fungal infections.In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?Liposomal Formulations in Clinical Use: An Updated Review.Nanodisks derived from amphotericin B lipid complex.Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization.Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.The amphotericin B lipid complex or Abelcet: its Belgian connection, its mode of action and specificity: a review.Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Serum pharmacology of amphotericin B applied in lipid emulsions.Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.Recommendations for the treatment of fungal pneumonias.The lipid formulations of amphotericin B.Amphotericin B is cytotoxic at locally delivered concentrations Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids.Amphotericin B: delivery systems.Carrier effects on biological activity of amphotericin B.Liposomes: realizing their promise.Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice.Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers.Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose.Amphotericin B lipid complex therapy of experimental fungal infections in mice Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.Liposomal nanomedicines.NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency Novel platforms for vascular carriers with controlled geometry.Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.

P2860

Q28328856-E9569D8E-4B45-4093-A498-87305FDD8898 Q28369708-332F0BAC-1486-455C-8671-D4D04DD06973 Q28379472-9D143673-4BFB-44F3-9710-1364E6591BC7 Q30436889-9F0C06BC-FCF9-4A47-B4C5-2F9A17649357 Q30452906-2C26DB66-5A42-4FFE-9FB0-E71E53890095 Q33304020-0D2E0E46-1C1F-472C-8712-DD7A1608A3C6 Q33604227-3ADFF2EB-92DD-475F-8E51-9593699C93F1 Q33692198-D2D417E6-F580-4748-BA4A-633D1D2E3CB4 Q33850427-B90AD550-9BF3-4F70-A23C-A925348BD393 Q33946918-802E1C32-8EBB-4365-8754-AC541276A0E8 Q33980180-915EA6C9-EF43-4C41-9517-E253607D266B Q33980885-77F4E841-1728-4B8D-A847-AB7E84E2B860 Q34160941-03F8A7ED-30A4-4369-A870-424C21172F6D Q34294886-1E402C10-5C68-4D0C-B067-A5F5C917484A Q34482076-6C7C438B-14C3-4598-833E-C667969F85D4 Q34763371-A5A1BA3C-BBA3-4875-934D-714775951CE5 Q34769519-316229F7-CF4C-449C-AC83-1D9162133B16 Q35122944-613D3134-AE7C-49C9-8398-6315D36E7CC8 Q35134565-49FD3280-DBB6-49D7-A2DA-F51055987A38 Q35138378-0B3C63ED-EEC6-467D-BFEB-627302F5BABF Q35183728-EA586615-1D4F-4AC4-9853-DC9EB5841312 Q35183734-27044CE3-3543-4F25-A3B5-CF1CEBAA489B Q35242794-82BD36DB-044E-4D6C-A975-4B8E56825321 Q35244905-A842920A-8FF3-4E0B-ACA8-C6CDFCF0FA65 Q35249721-7BE948D3-ACE2-497E-B091-58252C1F5903 Q35372581-0B10D905-FB99-4C5C-B46E-D5D8A97EBBE4 Q35550017-095FCACE-3FF7-4B04-ACC5-3201D0714F04 Q35824054-799AF64C-95C3-43A6-924B-85F01EDC57A0 Q35904665-F00D925F-867B-4737-BDB9-F74B51BB3AD8 Q36477796-5167A2E2-601A-4F33-8802-4F81DCA68446 Q36489697-A272AF02-69C1-4E11-ABC6-73DE8BA9C080 Q36752486-A0DC3DC6-22C7-41F5-A021-9EF4CAA31E57 Q36753279-55F70176-F0D1-4183-B7E3-18C0F794C740 Q36753723-FEBC1DF8-C406-4056-A434-22D5F71E976A Q36758184-48591B0F-1C46-40FE-9D8F-92D09BE9895A Q37039021-48E38506-0ED0-4C02-AD70-5632865A1724 Q37401889-54CF21E3-8D0D-4D61-A3D5-6EA966EF0B24 Q37896558-3E042B1E-A3FD-4E8B-A7B1-9EEF03ACCF80 Q37983912-9123C545-4DEB-458C-B646-FACB2657D15A Q38758771-977270F3-F50A-4ABE-A3C5-AFC66DA7AD92

P2860

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

http://www.wikidata.org/entity/Q33641360

description

1988 nî lūn-bûn

@nan

1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1988 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1988年の論文

@ja

1988年論文

@yue

1988年論文

@zh-hant

1988年論文

@zh-hk

1988年論文

@zh-mo

1988年論文

@zh-tw

1988年论文

@wuu

name

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@ast

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@en

type

label

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@ast

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@en

prefLabel

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@ast

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@en

P1433

Q33641360-DE5E65F2-08FD-499F-B20A-DCAC1F07BABD

P1476

Q33641360-B6EF311A-B04D-4FFC-9136-737C319D0214

P2093

Q33641360-0C242E7E-BF0F-436E-88D9-F77EA9A96424

Q33641360-0C756654-348A-4284-ACAA-9568A0BD2492

Q33641360-1B397BEF-45EC-4BD2-A504-D30392D98081

Q33641360-422273B8-0A15-4DBD-8352-AAF7A9A3CA59

Q33641360-5DB1638E-9A74-4DA1-9FB3-EC952561C6BE

Q33641360-9EE00EC7-2A45-4272-8EEF-D83F0B580488

Q33641360-CCBB8396-872C-4F0A-859A-92D2A64897BF

Q33641360-CE48E295-5A3B-42AF-BD1B-0DC92290810F

Q33641360-CFA8C703-C2EC-4580-BE9F-876422D6D5AD

Q33641360-F348D2A6-B53C-488D-B0C2-3FFBE2DF6A68

P2860

Q33641360-427F3979-ADA0-48BD-8402-FB2C0C933C82

Q33641360-4DDC652B-45F5-4730-B722-D5A1CA767009

Q33641360-6BD5B14F-3E52-4378-9C6D-D411FA4B190E

Q33641360-84472566-1763-43D2-9AB5-A1D660AE34C9

Q33641360-89E1E7D8-4089-4C3F-9EB7-6A40AFC72A99

Q33641360-951D0382-EBC2-410A-909B-BC15D7B0721D

Q33641360-EE74ACE6-7994-448C-998D-4C8F54A20126

Q33641360-FFB53F2A-FB3B-4A00-84B6-C82BB2555297

P304

Q33641360-E70D2AA1-4847-4D8C-95BC-487D3B5486CE

P31

Q33641360-519479E4-0DA1-463B-990B-BC8E57631710

P356

Q33641360-B76717A9-A73E-425D-809C-E45B2E353E74

P407

Q33641360-7CA647DA-2BE1-409F-98A1-01909209F883

P433

Q33641360-AE890B71-D3CF-4BD9-A83B-63A2009145DD

P478

Q33641360-EF6283E7-0A3F-4711-ADE7-4290F111FBC6

P577

Q33641360-8D8B76F0-01EF-4C12-98C5-04C2CE741DDF

P5875

Q33641360-CFF3E87E-BF92-4CF6-BAA7-9860E594E8F6

P698

Q33641360-117CDFC8-FF4E-4EEA-9D7B-60796C4FAA0E

P932

Q33641360-2F51411F-8552-4181-B7D7-A85C8E045073

P356

PNAS.85.16.6122

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

@en

P2093

Boni LT

http://www.w3.org/2001/XMLSchema#string

Cullis PR

http://www.w3.org/2001/XMLSchema#string

Gruner SM

http://www.w3.org/2001/XMLSchema#string

Janoff AS

http://www.w3.org/2001/XMLSchema#string

Madden TD

http://www.w3.org/2001/XMLSchema#string

Minchey SR

http://www.w3.org/2001/XMLSchema#string

Popescu MC

http://www.w3.org/2001/XMLSchema#string

Shyamsunder E

http://www.w3.org/2001/XMLSchema#string

Taraschi T

http://www.w3.org/2001/XMLSchema#string

Tate MW

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles.

31P nuclear magnetic resonance and the head group structure of phospholipids in membranes.

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study.

Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

Interaction of amphotericin B with membrane lipids as viewed by 2H-NMR.

P304

6122-6126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.85.16.6122

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

1988-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

19743415

http://www.w3.org/2001/XMLSchema#string

P698

3413081

http://www.w3.org/2001/XMLSchema#string

P932

281917

http://www.w3.org/2001/XMLSchema#string